grant
Bioinstructive Scaffolds for Potent and Affordable CAR-T Cell Therapy Against Brain Tumors
Organization UNIV OF NORTH CAROLINA CHAPEL HILLLocation CHAPEL HILL, UNITED STATESPosted 27 Aug 2024Deadline 28 Feb 2029
NIHUS FederalResearch GrantFY2025AbscissionAfter CareAfter-TreatmentAftercareAlginatesAntibodiesAntigensB cell malignancyB lymphoid malignancyB7-H3B7H3Biocompatible MaterialsBiomaterialsBloodBlood - brain barrier anatomyBlood Reticuloendothelial SystemBlood-Brain BarrierBrainBrain CancerBrain NeoplasiaBrain NeoplasmsBrain Nervous SystemBrain TumorsCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD276CD276 geneCD28CD28 geneCancersCell BodyCellsClinicClinicalClinical TrialsClinical Trials DesignCo-StimulatorCostimulatorDataDevelopmentDiseaseDisorderDoseEncapsulatedEncephalonEngraftmentEpidermal Thymocyte Activating FactorExcisionExtirpationGenerationsGlioblastomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaHemato-Encephalic BarrierIL-2IL2 ProteinImmune mediated therapyImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyImplantInfusionInfusion proceduresInterleukin 2Interleukin 2 PrecursorInterleukin IIInterleukin-2Interleukine 2Interleukine 2 PrecursorInterleukine IIInterleukinsIntrasurgical Resection CavityIntraventricularKineticsLiquid substanceLymphocyte Mitogenic FactorMalignant NeoplasmsMalignant TumorMalignant Tumor of the BrainMalignant neoplasm of brainMediatingMedicalMethodsMitogenic FactorModalityModelingNatureNon-Hodgkin's LymphomaNonhodgkins LymphomaOperative ProceduresOperative Surgical ProceduresOrganPBMCPatient IsolationPatientsPeripheral Blood Mononuclear CellPhenotypePreparationPrimary Brain NeoplasmsPrimary Brain TumorsProliferatingPropertyPublic HealthPublishingRadiation therapyRadiotherapeuticsRadiotherapyRecurrenceRecurrentRecurrent NeoplasmRecurrent tumorRemovalResectedResection CavityRetroviral VectorRetroviridaeRetrovirus VectorRetrovirusesRheologyRouteSolidSolid NeoplasmSolid TumorSpeedStructureSurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalSurgically-Created Cystic Resection CavitySurgically-Created Resection CavitySwellingSymptomsT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell growth factorT cell immune therapyT cell immunotherapyT cell infiltrationT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cells for CART cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-Cell ActivationT-Cell Growth FactorT-Cell Stimulating FactorT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyT44TechnologyTemodalTemodarTestingTherapeuticThymocyte Stimulating FactorTimeToxic effectToxicitiesTranslatingTranslationsTreatment EfficacyViralVirusVirus-Retrovirusactivate T cellsadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapybiocompatibilitybiological materialbiomaterial compatibilitybiomaterial scaffoldbioscaffoldbloodbrain barriercell transductioncellular transductionchimeric antigen T cell receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical applicabilityclinical applicationclinical translationclinically translatablecostdensitydetermine efficacydevelopmentalefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationengineered T cellsevaluate efficacyexamine efficacyfluidgenetically engineered T-cellsglioblastoma multiformeimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimplantationimprovedin vivoinfusionsinnovateinnovationinnovativeintervention efficacyliquidmalignancymanufacturemanufacturing processmethazolastonemultidisciplinaryneoplasm recurrenceneoplasm/cancerneurosurgerynon-Hodgkins diseaseoverexpressoverexpressionpatient populationpost treatmentpre-clinicalpre-clinical trialpreclinicalpreclinical trialpreparationspreventpreventingradiation treatmentresectionresponsescaffoldscaffoldingspongioblastoma multiformesuccesssurgerytechnology platformtechnology systemtemozolomidetherapeutic T-cell platformtherapeutic efficacytherapeutic targettherapy efficacythymus derived lymphocytetooltransduced cellstransgenic T- cellstranslationtreatment with radiationtumortumors in the brainventricular system
Description preview
PROJECT SUMMARY
Glioblastoma multiforme (GBM) is a fatal and difficult to treat brain tumor with a dismal median survival of less
than 2 years. Standard therapy consists of surgical tumor resection, radiotherapy, and temozolomide, which only
delay tumor recurrence. Recent success of CAR T cell therapy against Non-Hodgkin’s Lymphomas have gener-…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click